Last edition
News about "Bill Haney"
Skyhawk Therapeutics has entered a strategic research collaboration worth over USD 2 billion with Merck KGaA, Darmstadt, Germany to develop novel RNA-targeting small molecules for neurological disorders.
Bill Haney | 19/08/2025 | By Mrinmoy Dey | 158
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members